Tessera
Folgen

Angela Cochran

@acochran12733.bsky.social

Publisher at ASCO; football, softball, and theater mom; former president of SSP and CSE. Scholarly Kitchen chef. Girl Scout leader. All posts my own unless stolen from someone way smarter. #oncsky

224 Posts1562 Follower1276 Folgt
Angela Cochran@acochran12733.bsky.social · 4mo ago

Join me for CSE's "Business of Publication Management" course. Topics include: business models & revenue; AI strategy; Financial portfolio management; Succession planning; and more! cse.memberclicks.net/short-course... #ScholarlyPublishing #AcademicPublishing #CareerDev #OpenAccess #AI

a boy in a blue shirt is standing on a chair in front of a classroom full of children .

Alt: a boy in a blue shirt is standing on a chair in front of a classroom full of children and dancing.

media.tenor.com

Angela Cochran@acochran12733.bsky.social · 5mo ago

We are all in this together! Todd Toler and I interviewed 14 colleagues about various aspects of AI in their publishing programs and organizations. Part 1 focuses on strategy, leadership, and licensing. scholarlykitchen.sspnet.org/2026/03/11/w...

What Publishing Leaders Say About AI When They're Not on Panels: A Pulse on All Things AI - The Scholarly Kitchen

Today's post explores issues facing scholarly publishers around AI — using it, layering it, competing against it, and licensing to it.

scholarlykitchen.sspnet.org

Society for Translational Oncology@sto-online.org · 8mo ago

Review highlights gaps and opportunities to expand cancer clinical trials in Latin America, a region with rising cancer burden but <2% of global trial activity. Read more: buff.ly/tVPqGO3 #GlobalOncology #ClinicalTrials #LatinAmerica

Challenges and Opportunities for Cancer Clinical Trials Development in Latin America | JCO Global Oncology

Despite accounting for over 8% of the global population and bearing a growing cancer burden, Latin America (LATAM) contributes <2% of global oncology trial activity and scientific output. Beyond…

buff.ly

Stacey Tinianov, MPH@coffeemommy.bsky.social · last yr.

A pleasure and an honor to join @fumikochino.bsky.social & Dr. Ethan Ludmir in this @ascocancer.bsky.social conversation on incomplete reporting and toxicity- minimizing language in oncology! 💗

Fumiko Ladd Chino, MD FASCO@fumikochino.bsky.social · last yr.

“When choosing cancer therapies, people should not have to choose between being alive & living”   Toxicity minimizing language ("safe” & “tolerable”) are subjective & can downplay QOL limiting side effects from treatment. 🚨New @ascocancer.bsky.social Podcast is live today! @coffeemommy.bsky.social

Angela Cochran@acochran12733.bsky.social · last yr.

I don't agree with their peer review model, but the premise here is correct. There are rules of indexing and citation counting that are keeping journals from transforming into modern publication systems.

eLife@elife.bsky.social · last yr.

“Journals and peer review are unlikely to change for the better if the companies that operate scientific indexes and citation databases continue to stifle innovation.” Read our guest post in DORA: buff.ly/EGDbskH

Angela Cochran@acochran12733.bsky.social · last yr.

Agree. At least a decade of pushing our kids to STEM only. Result: few can critically read or write, entry level computer science/coding jobs were the 1st to get cut with AI, decrease in kids wanting to be physicians.

Glen O'Hara@gsoh31.bsky.social · last yr.

Decades of mechanistic talk about university degrees as if they were bundles of 'skills' and 'prep' are about to be proved completely wrong (obviously). Want to get a real boost? Do History or English.

Richard Van Noorden@richvn.bsky.social · last yr.

Yep. Prestige costs money to create (literally: highly-selective journals are more expensive to run in part because of their selectivity, not to mention their staff). And, if gold OA is to be the model, then author or their funders are agreeing to pay per paper for that prestige.

Mandi Lindner@mandilindner.bsky.social · last yr.

There's also a helpful criticism here that, if we have to constantly and meticulously double check the work of AI then is it a tool that really saves us time and effort? And, given that cost/benefit ratio, what are the actual use cases that make using it worthwhile?

American Society of Clinical Oncology@ascocancer.bsky.social · last yr.

Just announced: ASCO and Google Cloud launch the ASCO Guidelines Assistant, an AI tool for fast access to ASCO's trusted and expert-developed clinical cancer guidelines. Read more in @statnews.com

ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines

ASCO and Google Cloud's AI tool is meant to help oncologists query just its trusted cancer treatment guidelines, without extraneous information.

statnews.com